Download PDF
Arzneimittelforschung 2010; 60(10): 599-606
DOI: 10.1055/s-0031-1296332
CNS-active Drugs · Hypnotics · Psychotropics · Sedatives
Editio Cantor Verlag Aulendorf (Germany)

A sensitive and selective HPLC method for estimation of lamotrigine in human plasma and saliva: application to plasma-saliva correlation in epileptic patients

Surulivel Rajan Mallayasamy
1   Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Karthik Arumugam
1   Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Tarun Jain
1   Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Thiyagu Rajakannan
1   Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Krishnamurthy Bhat
1   Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Padma Gurumadhavrao
1   Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Ramakrishna Devarakonda
2   Covidien/Mallinckrodt, Inc, Clinical Research Division, Hazelwood, Missouri, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
03 December 2011 (online)

    Permissions and Reprints

Abstract

A sensitive and selective high performance liquid chromatographic (HPLC) method was developed and validated for estimation of lamotrigine (CAS 84057-84-1) in human plasma and saliva. The chromatographic separation was achieved with a reversed phase column and a mobile phase consisting of acetonitrile and 20 mM ammonium acetate buffer pH 6.5 (30:70) with a flow rate of 1 mL/min. The calibration curve was linear within the working range for both plasma and saliva. The validated method has been successfully applied for a study of lamotrigine in human plasma and saliva to establish the correlation between these two matrices. A scatter plot of plasma versus salivary lamotrigine concentrations showed a good linear relationship between them (Pearson correlation coefficient, r = 0.6832, p < 0.001).

Key words

Antiepileptic drug - CAS 84057-84-1 - HPLC method - Lamotrigine, pharmacokinetics, plasma-saliva correlation
 

  • References

  • 1 Gidal BE, Sheth R, Parbell J, Maloney JK, Sale M. Evaluation of valproate dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res. 2003; 57: 85-93
    CrossrefPubMedGoogle Scholar
  • 2 Lamictal prescriping information. [Internet] Glaxo-SmithKlineBeecham; 1994 [updated September 2009; cited 2009 Dec 26] [about 4 screens]. Available from: http://us.gsk.com/product/assets/us_lamictal.pdf
    PubMed
  • 3 Chkhartishvili D, Natriashvili G. Lamotrigine monotherapy for pharmacoresistant complex partial seizures in children with hippocampal atrophy. Clin Neurophysiol. 1996; 117 (01) 127-9
    PubMedGoogle Scholar
  • 4 Kilpatrick ES, Forrest G, Brodie MJ. Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. Epilepsia. 2001; 42: 1255-60
    CrossrefPubMedGoogle Scholar
  • 5 Hirsch LJ, Weintraub D, Du Y, Bauchsbaum R, Spencer HT, Hager M et al. Correlating lamotrigine concentrations with tolerability in patients with epilepsy. Neurology. 2004; 63: 1022-6
    CrossrefPubMedGoogle Scholar
  • 6 Incecayir T, Agabeyoglu I, Gucuyener K. Comparison of plasma and saliva concentrations of lamotrigine in healthy volunteers. Arzneimittelforschung. 2007; 57 (8) 517-21
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Malone SA, Eadie MJ, Addison RS, Wright AW, Dickinson RG. Monitoring salivary lamotrigine concentrations. J Clin Neurosci. 2006; 3 (9) 902-7
    PubMedGoogle Scholar
  • 8 Ryan M, Grim SA, Miles MV, P. Tang PH, Fakhoury TA, Strawsburg RH et al. Correlation of lamotrigine concentrations between serum and saliva. Pharmacotherapy. 2003; 23 (12) 1550-7
    CrossrefPubMedGoogle Scholar
  • 9 Trnavska Z, Krejcova H, Tkaczykovam. Salcmanova Z, Elis J. Pharmacokinetics of lamotrigine (Lamictal) in plasma and saliva. Eur J Drug Metab Pharmacokinet. 1991; 3: 211-5
    PubMedGoogle Scholar
  • 10 Tsiropouolos I, Kristensen O, Klitgaard NA. Saliva and serum concentration of lamotrigine in patients with epilepsy. Ther Drug Monit. 2000; 22: 517-21
    CrossrefPubMedGoogle Scholar
  • 11 Vermeij TAC, Edelbroek PM. Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction. J Chromatogr B. 2007; 828 (1–2) 85-93
    PubMedGoogle Scholar
  • 12 Bugamelli F, Sabbioni C, Mandrioli R, Kenndler E, Albani F, Raggi MA. Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatography after solid-phase extraction. Anal Chim Acta. 2002; 472 (1) 1-10
    CrossrefPubMedGoogle Scholar
  • 13 Yamashita S, Furuno K, Kawasaki H, Gomita Y, Yoshinaga H, Yamatogi Y et al. Simple and rapid analysis of lamotrigine, a novel antiepileptic, in human serum by high-performance liquid chromatography using a solid-phase extraction technique. J Chromatogr B. 1995; 670 (2) 354-7
    PubMedGoogle Scholar
  • 14 Castel-Branco MM, Almeida AM, Falcão AC, Macedo TA, Caramona MM, Lopez FG. Lamotrigine analysis in blood and brain by high-performance liquid chromatography. J Chromatogr B. 2001; 755 (1–2) 119-27
    PubMedGoogle Scholar
  • 15 Manuela C, Monica B, Erica C, Carmina C, Fiorenzo A, Roberto R et al. Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. J Chromatogr B. 2005; 828: 113-7
    CrossrefPubMedGoogle Scholar
  • 16 Matar KM, Nicholls PJ, Bawazir SA, Al-Hassan MI, Tekle A. A rapid liquid chromatographic method for the determination of lamotrigine in plasma. J Pharm Biomed Anal. 1998; 17: 525-531
    CrossrefPubMedGoogle Scholar
  • 17 Patil KM, and Bodhankar SL. Simultaneous determination of lamotrigine, phenobarbitone, carbamazepine and phenytoin in human serum by high-performance liquid chromatography. J Pharm Biomed Anal. 2005; 39 (1–2) 181-186
    CrossrefPubMedGoogle Scholar
  • 18 Ching LC, Chen HC, Oliver YP. Determination of lamotrigine in small volumes of plasma by high-performance liquid chromatography. J Chromatogr B. 2005; 828: 113-7
    CrossrefPubMedGoogle Scholar
  • 19 Angelis SP, Morgan DJ, O’Brien TJ, Vajda FJE. Determination of lamotrigine in human plasma by high-performance liquid chromatography. J Chromatogr B. 1999; 727: 113-8
    PubMedGoogle Scholar
  • 20 Londero D, Greco PL. New micro method for the determination of lamotrigine in human plasma by high-performance liquid chromatography. J Chromatogr B. 1997; 691: 139-44
    PubMedGoogle Scholar
  • 21 Bompadre S, Tagliabracci A, Battino M, Giorgetti R. Determination of lamotrigine in whole blood with on line solid phase extraction. J Chromatogr B. 2008; 863 (1) 177-80
    CrossrefPubMedGoogle Scholar
  • 22 Torra M, Rodamilans M, Arroyo S, Corbella J. Optimized procedure for lamotrigine analysis in serum by high-performance liquid chromatography without interferences from other frequently co-administered anticonvulsants. Ther Drug Monit. 2000; 22 (5) 621-5
    CrossrefPubMedGoogle Scholar
  • 23 Croci D, Salmaggi A, De Grazia U, Bemardi G. New high-performance liquid chromatographic method for plasma/serum analysis of lamotrigine. Ther Drug Monit. 2001; 23 (6) 665-8
    CrossrefPubMedGoogle Scholar
  • 24 Sallustio BC, Morris RG. High-performance liquid chromatography quantitation of plasma lamotrigine concentrations: application measuring trough concentrations in patients with epilepsy. Ther Drug Monit. 1997; 19 (6) 688-93
    CrossrefPubMedGoogle Scholar
  • 25 Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med. 1996; 334: 1583-90
    CrossrefPubMedGoogle Scholar
  • 26 Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol. 1998; 46: 547-51
    PubMedGoogle Scholar
  • 27 Guidance for industry. Bioanalytical method validation [Internet]. Bethesda (MD): Food and Drug Administration, Center for Drug Evaluation and Research, (US); May 2001 [cited 2009 Dec 26] [about 25 screens]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformationlGuidanceslUCM070107.pdf
    PubMed